Doxapram-d8

Doxapram-d8

• UNSPSC Description: Doxapram-d8 is deuterated labeled Doxapram (HY-B0551). Doxapram inhibits TASK-1, TASK-3 and TASK-1/TASK-3 heterodimer channels with EC50s of 410 nM, 37 μM and 9 μM, respectively.
• Target Antigen: Isotope-Labeled Compounds; Potassium Channel
• Type: Isotope-Labeled Compounds
• Related Pathways: Membrane Transporter/Ion Channel;Others
• Applications: Neuroscience-Neuromodulation
• Field of Research: Neurological Disease
• Solubility: 10 mM in DMSO
• Smiles: O=C1N(CC)CC(CCN2C([2H])([2H])C([2H])([2H])OC([2H])([2H])C2([2H])[2H])C1(C3=CC=CC=C3)C4=CC=CC=C4
• Molecular Weight: 386.56
• References & Citations: [1]Cotten JF, et al. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg, 2006, 102(3), 779-785.|[2]Peers, C., Effects of doxapram on ionic currents recorded in isolated type I cells of the neonatal rat carotid body. Brain Res, 1991. 568(1-2): p. 116-22.|[3]Anderson-Beck, R., et al., Doxapram stimulates dopamine release from the intact rat carotid body in vitro. Neurosci Lett, 1995. 187(1): p. 25-8.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported